Monoclonal antibody targeting complement C1s, blocking the classical complement pathway. Engineered with YTE half-life extension for infrequent subcutaneous self-administration.
Dosing Notes
Investigational; subcutaneous dosing every 2 weeks in current trial.
Treatment Type
pharmaceutical
Clinical Evidence
What the Evidence Shows
Each finding below is linked to its primary source. Confidence levels reflect the quality and quantity of available evidence — not CelluTarget's endorsement of any treatment.
High: Supported by multiple robust studies or regulatory approval
Moderate: Supported by limited controlled studies or consistent case series
Low: Based on case reports, expert opinion, or early-phase data only
Low ConfidenceBased on case reports, expert opinion, or early-phase data only